126 related articles for article (PubMed ID: 35021421)
1. Anti-MUC1/CD44 Dual-Aptamer-Conjugated Liposomes for Cotargeting Breast Cancer Cells and Cancer Stem Cells.
Kim DM; Kim M; Park HB; Kim KS; Kim DE
ACS Appl Bio Mater; 2019 Oct; 2(10):4622-4633. PubMed ID: 35021421
[TBL] [Abstract][Full Text] [Related]
2. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
4. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin through CD44 aptamer to cancer cells.
Natesh J; Chandola C; Meeran SM; Neerathilingam M
Ther Deliv; 2021 Oct; 12(10):693-703. PubMed ID: 34592836
[No Abstract] [Full Text] [Related]
6. Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.
Dai B; Hu Y; Duan J; Yang XD
Oncotarget; 2016 Jun; 7(25):38257-38269. PubMed ID: 27203221
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model.
Zhou K; Huo X; Nguyen R; Bae SDW; Han S; Zhang Z; Duan W; Yuen L; Lam V; George J; Qiao L
J Control Release; 2022 Jan; 341():341-350. PubMed ID: 34848243
[TBL] [Abstract][Full Text] [Related]
9. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
[TBL] [Abstract][Full Text] [Related]
10. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
Liu X; Wu L; Wang L; Jiang W
Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
[TBL] [Abstract][Full Text] [Related]
11. Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells
Xing H; Tang L; Yang X; Hwang K; Wang W; Yin Q; Wong NY; Dobrucki LW; Yasui N; Katzenellenbogen JA; Helferich WG; Cheng J; Lu Y
J Mater Chem B; 2013 Oct; 1(39):5288-5297. PubMed ID: 24159374
[TBL] [Abstract][Full Text] [Related]
12. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro.
Hu Y; Duan J; Zhan Q; Wang F; Lu X; Yang XD
PLoS One; 2012; 7(2):e31970. PubMed ID: 22384115
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
14. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
15. Engineering of Bone- and CD44-Dual-Targeting Redox-Sensitive Liposomes for the Treatment of Orthotopic Osteosarcoma.
Feng S; Wu ZX; Zhao Z; Liu J; Sun K; Guo C; Wang H; Wu Z
ACS Appl Mater Interfaces; 2019 Feb; 11(7):7357-7368. PubMed ID: 30682240
[TBL] [Abstract][Full Text] [Related]
16. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
17. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
[TBL] [Abstract][Full Text] [Related]
18. PrP
Go G; Lee CS; Yoon YM; Lim JH; Kim TH; Lee SH
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671292
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells.
Haggag Y; Abu Ras B; El-Tanani Y; Tambuwala MM; McCarron P; Isreb M; El-Tanani M
Expert Opin Drug Deliv; 2020 Nov; 17(11):1655-1669. PubMed ID: 32841584
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes.
Song X; Ren Y; Zhang J; Wang G; Han X; Zheng W; Zhen L
Oncol Rep; 2015 Oct; 34(4):1953-60. PubMed ID: 26238192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]